PepGen Inc. (PEPG)
NASDAQ: PEPG · Real-Time Price · USD
4.300
-0.100 (-2.27%)
Nov 21, 2024, 1:21 PM EST - Market open
Company Description
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases.
Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.
The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD.
PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts.
PepGen Inc.
| Country | United States |
| Founded | 2018 |
| IPO Date | May 6, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 64 |
| CEO | James McArthur |
Contact Details
Address: 321 Harrison Avenue, 8th Floor Boston, Massachusetts 02118 United States | |
| Phone | 781 797 0979 |
| Website | pepgen.com |
Stock Details
| Ticker Symbol | PEPG |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $12.00 |
| CIK Code | 0001835597 |
| CUSIP Number | 713317105 |
| ISIN Number | US7133171055 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. James G. McArthur Ph.D. | President, Chief Executive Officer, Treasurer, Secretary and Director |
| Noel P. Donnelly M.B.A. | Chief Financial Officer |
| Dr. Michelle L. Mellion M.D. | Chief Medical Officer |
| Dr. Michael Gait Ph.D. | Founder and Scientific Advisory Board Member |
| David E. Borah C.F.A. | Senior Vice President of IR and Corporate Communications |
| Mary Beth DeLena J.D. | General Counsel and Secretary |
| Niels Svenstrup Ph.D. | Senior Vice President of Chemistry, Manufacturing and Control |
| Emiko Bryant | Chief of Staff |
| Dr. Hayley Parker Ph.D. | Senior Vice President of Global Regulatory Affairs |
| Dr. Afsaneh Mohebbi Ph.D. | Senior Vice President of Portfolio and Program Management |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 7, 2024 | 10-Q | Quarterly Report |
| Nov 7, 2024 | 8-K | Current Report |
| Oct 8, 2024 | 8-K | Current Report |
| Sep 19, 2024 | 8-K | Current Report |
| Aug 20, 2024 | 8-K | Current Report |
| Aug 12, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Aug 8, 2024 | 10-Q | Quarterly Report |